Nothing Special   »   [go: up one dir, main page]

WO2011030872A1 - Composés sulfonamide - Google Patents

Composés sulfonamide Download PDF

Info

Publication number
WO2011030872A1
WO2011030872A1 PCT/JP2010/065658 JP2010065658W WO2011030872A1 WO 2011030872 A1 WO2011030872 A1 WO 2011030872A1 JP 2010065658 W JP2010065658 W JP 2010065658W WO 2011030872 A1 WO2011030872 A1 WO 2011030872A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
phenyl
alkyl
halogeno
alkoxy
Prior art date
Application number
PCT/JP2010/065658
Other languages
English (en)
Japanese (ja)
Inventor
亮 岩村
哲嗣 勝部
栄治 岡成
学 重冨
裕仁 徳永
Original Assignee
宇部興産株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 宇部興産株式会社 filed Critical 宇部興産株式会社
Publication of WO2011030872A1 publication Critical patent/WO2011030872A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to a novel sulfonamide compound useful as a medicine or a pharmacologically acceptable salt thereof. More specifically, since the sulfonamide compound according to the present invention has an EP2 agonistic action, for example, a therapeutic agent and / or prevention for respiratory diseases such as asthma and chronic obstructive pulmonary disease (hereinafter abbreviated as COPD). Useful as a medicine.
  • a therapeutic agent for example, a therapeutic agent and / or prevention for respiratory diseases such as asthma and chronic obstructive pulmonary disease (hereinafter abbreviated as COPD).
  • COPD chronic obstructive pulmonary disease
  • PGE 2 prostaglandin E 2
  • PGE 2 is known to act as an agonist for receptors such as EP1, EP2, EP3, and EP4, and among them, the agonistic action for EP2 receptor is deeply involved in the bronchodilating action.
  • EP1, EP2, EP3, and EP4 the agonistic action for EP2 receptor is deeply involved in the bronchodilating action.
  • Patent Documents 1 to 4 it is known that sulfonamide compounds having a structure similar to the compound of the present invention have EP2 agonistic activity (see Patent Documents 1 to 4).
  • the compound described as Example 14e in Patent Document 2 has an effect of accelerating the healing of fractures by increasing the concentration of cyclic adenosine monophosphate (hereinafter abbreviated as cAMP) by the EP2 agonist action.
  • cAMP cyclic adenosine monophosphate
  • Non-Patent Document 3 it is not specifically described that the compounds described in Patent Documents 1 to 4 have a bronchodilator action due to EP2 agonistic action, and none of the above-mentioned documents describes the sulfone according to the compound of the present invention. There is no specific disclosure about amide compounds.
  • a new sulfonamide compound having a specific structure is a powerful compound. It has excellent bronchodilator action based on EP2 agonist action, and further, tissue transferability, bioavailability (BA), rapid onset of drug effect, sustained drug effect, solubility, physical stability, drug interaction Since it has excellent properties in terms of action and toxicity, it has been found that it is particularly useful as a therapeutic and / or preventive agent (preferably a therapeutic agent) for respiratory diseases such as asthma and COPD. Was completed.
  • the present invention has a novel bronchodilator action based on a strong EP2 agonist action, and is particularly useful as a therapeutic agent and / or preventive agent (preferably a therapeutic agent) for respiratory diseases such as asthma and COPD.
  • a sulfonamide compound or a pharmacologically acceptable salt thereof is provided.
  • the “sulfonamide compound” in the present invention means a compound represented by the following general formula (I).
  • R 1 represents a hydrogen atom, a C 1 -C 6 alkyl group or a halogeno C 1 -C 6 alkyl group
  • R 2 and R 3 each independently represents a hydrogen atom or a C 1 -C 6 alkyl group
  • Y represents any of the following (a) to (d);
  • A A group consisting of a halogeno group, a C 1 -C 6 alkyl group, a halogeno C 1 -C 6 alkyl group, a C 1 -C 6 alkoxy group, a halogeno C 1 -C 6 alkoxy group and a C 1 -C 6 alkylthio group Or a bicyclic heteroaromatic group optionally substituted with the same or different 1 to 5 groups selected from (B) group -Q 1 -Q 2 (wherein Q 1 represents an arylene group or a 5- to 6-membered heteroarylene group, Q 2 represents a halogeno group, a hydroxy group, a
  • a heterocyclic group, Z is a C 1 -C 6 alkyl group, C 3 -C 8 cycloalkyl group, C 5 -C 8 cyclo group which may be substituted with the same or different 1 to 3 groups selected from the substituent group ⁇ .
  • An aryl group except a halogeno group, a C 1 -C 6 alkyl group, a halogeno C 1 -C 6 alkyl group, a C 1 -C 6 alkoxy group and a halogeno C 1 -C 6 alkoxy group as a substituent
  • a heteroaryl group however, a halogeno group, a C 1 -C 6 alkyl group, a halogeno C 1 -C 6 alkyl group, a C 1 -C 6 alkoxy group and a halogeno C 1 -C 6 alkoxy group are excluded as a substituent
  • Substituents included in the substituent group ⁇ are hydroxy group, oxo group,
  • the sulfonamide compound represented by the general formula (I) of the present invention or a pharmacologically acceptable salt thereof exhibits an excellent bronchodilator action based on a strong EP2 agonist action, and further, tissue transferability, bioavailability (bioavailability).
  • BA tissue transferability, bioavailability (bioavailability).
  • BA rapid onset of drug efficacy, sustained drug efficacy, solubility, physical stability, drug interaction, toxicity, etc.
  • respiratory disease for example, A novel compound having excellent properties as a therapeutic and / or prophylactic agent for asthma, COPD, bronchitis, emphysema, pulmonary fibrosis, acute respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary hypertension, etc.
  • ARDS acute respiratory distress syndrome
  • cystic fibrosis pulmonary hypertension, etc.
  • the compound represented by the general formula (1) of the present invention is also useful as a therapeutic and / or prophylactic agent for diseases (for example, bone diseases, gastric ulcers, hypertension, glaucoma, etc.) for which EP2 agonist action is considered useful. It is.
  • diseases for example, bone diseases, gastric ulcers, hypertension, glaucoma, etc.
  • C 1 -C 6 alkyl group represented by each substituent and the “C 1 -C 6 alkyl group” portion in each substituent each mean a “C 1 -C 6 alkyl group” having the same meaning.
  • Examples of such “C 1 -C 6 alkyl group” include, for example, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, Isopentyl group, neopentyl group, tert-pentyl group, 1-methylbutyl group, 2-methylbutyl group, 1-ethylpropyl group, 1,2-dimethylpropyl group, hexyl group, 1-methylpentyl group, 2-methylpentyl group, 3-methylpentyl group, 4-methylpentyl group, 1-ethylbutyl group, 2-ethylbutyl group,
  • halogeno C 1 -C 6 alkyl group represented by each substituent means a “halogeno C 1 -C 6 alkyl group” having the same significance, and such a “halogeno C 1 -C 6 alkyl group” Are, for example, trifluoromethyl group, difluoromethyl group, fluoromethyl group, trichloromethyl group, dichloromethyl group, chloromethyl group, pentafluoroethyl group, 2,2,2-trifluoroethyl group, 2-fluoro Ethyl group, 2,2,2-trichloroethyl group, 2-chloroethyl group, 2-bromoethyl group, heptafluoropropyl group, 3,3,3-trifluoropropyl group, 3-fluoropropyl group, 3-chloropropyl group 1,2,2,2-tetrafluoro-1-trifluoromethylethyl group, 2,2,2-trifluoro-1-methylethyl group
  • Y Substituted by the aryl group or 5- to 6-membered heterocyclic group represented by Y, represented by the following formula (II)
  • the “C 1 -C 12 alkyl group” represented by R 4 in the formula for example, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, Isopentyl group, neopentyl group, tert-pentyl group, 1-methylbutyl group, 2-methylbutyl group, 1,2-dimethylpropyl group, 1-ethylpropyl group, hexyl group, 1-methylpentyl group, 2-methylpentyl group, 3-methylpentyl group, 4-methylpentyl group, 1-ethylbutyl group, 2-ethylbutyl group, 1,1-dimethylbutyl group, 2,2-d
  • the “C 2 -C 6 alkenyl group” represented by each substituent means a “C 2 -C 6 alkenyl group” having the same meaning, and as such a “C 2 -C 6 alkenyl group”,
  • vinyl group 1-propenyl group, 2-propenyl group, isopropenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1-methyl-1-propenyl group, 2-methyl-1- Propenyl group, 1-methyl-2-propenyl group, 2-methyl-2-propenyl group, 1-ethylvinyl group, 1-pentenyl group, 2-pentenyl group, 3-pentenyl group, 4-pentenyl group, 1-methyl- 1-butenyl group, 2-methyl-1-butenyl group, 3-methyl-1-butenyl group, 1-methyl-2-butenyl group, 2-methyl-2-butenyl group, 3-methyl-2-butenyl group, 1-methyl -3-butenyl,
  • the “C 2 -C 6 alkynyl group” represented by each substituent means a “C 2 -C 6 alkynyl group” having the same meaning, and as such a “C 2 -C 6 alkynyl group”,
  • ethynyl group 1-propynyl group, 2-propynyl group, 1-butynyl group, 2-butynyl group, 3-butynyl group, 1-methyl-2-propynyl group, 1-pentynyl group, 2-pentynyl group, 3-pentynyl group, 4-pentynyl group, 3-methyl-1-butynyl group, 1-methyl-2-butynyl group, 1-methyl-3-butynyl group, 2-methyl-3-butynyl group, 1-ethyl- 2-propynyl group, 1-hexynyl group, 2-hexynyl group, 3-hexynyl group, 4-hexynyl group, 5-
  • Base More preferred is a 2-propynyl group, 2-butynyl group, 3-butynyl group, 2-pentynyl group, 3-pentynyl group or 4-pentynyl group, and particularly preferred is a 2-propynyl group or 2-butynyl group. is there.
  • C 3 -C 8 cycloalkyl group indicated by each substituent, "C 3 -C 8 cycloalkyl group” moiety in each substituent both have the same meaning "C 3 -C 8 cycloalkyl group means ", such as” C 3 -C 8 cycloalkyl group ", for example, cyclopropyl group, cyclobutyl group, cyclopentyl group, C 3 -C 8, such as a cyclohexyl group, cycloheptyl group or cyclooctyl group
  • a cycloalkyl group preferably a cyclopropyl group, a cyclobutyl group, a cyclopentyl group or a cyclohexyl group, more preferably a cyclopropyl group, a cyclobutyl group or a cyclopentyl group, particularly preferably a cyclopropyl group or a cyclobutyl group.
  • the “C 5 -C 8 cycloalkenyl group” represented by each substituent means a “C 5 -C 8 cycloalkenyl group” having the same meaning, and such a “C 5 -C 8 cycloalkenyl group”.
  • cyclopentenyl cyclopenten-3-yl, cyclohexenyl, cyclohexen-3-yl, cyclohexen-4-yl, cycloheptenyl, cyclohepten-3-yl, cyclohepten-4-yl Group, cyclohepten-5-yl group, cyclooctenyl group, cycloocten-3-yl group, cycloocten-4-yl group, cycloocten-5-yl group and the like, and preferred are C 5 -C 8 cycloalkenyl groups.
  • cyclopentenyl group is a C 5 -C 6 cycloalkenyl group, more preferably, cyclopentenyl group, cyclopentene -3 A yl group or a cyclohexenyl group, particularly preferably a cyclopentenyl group or cyclohexenyl group.
  • the “C 1 -C 6 alkoxy group” represented by each substituent and the “C 1 -C 6 alkoxy group” part in each substituent each mean a “C 1 -C 6 alkoxy group” having the same meaning.
  • Examples of such “C 1 -C 6 alkoxy group” include methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, pentyloxy Group, isopentyloxy group, neopentyloxy group, tert-pentyloxy group, 1-methylbutoxy group, 2-methylbutoxy group, 1-ethylpropoxy group, 1,2-dimethylpropoxy group, hexyloxy group, 1- Methylpentyloxy group, 2-methylpentyloxy group, 3-methylpentyloxy group, 4-methylpentyloxy group, 1- Tylbutoxy group, 2-ethylbutoxy group, 1,1-d
  • halogeno C 1 -C 6 alkoxy group represented by each substituent means a “halogeno C 1 -C 6 alkoxy group” having the same significance, and such a “halogeno C 1 -C 6 alkoxy group”.
  • trifluoromethoxy group difluoromethoxy group, trichloromethoxy group, dichloromethoxy group, pentafluoroethoxy group, 2,2,2-trifluoroethoxy group, 2-fluoroethoxy group, 2,2,2 -Trichloroethoxy group, 2-chloroethoxy group, 2-bromoethoxy group, heptafluoropropoxy group, 3,3,3-trifluoropropoxy group, 3-fluoropropoxy group, 3-chloropropoxy group, 1,2,2 , 2-tetrafluoro-1-trifluoromethylethoxy group, 2,2,2-trifluoro-1-methylethoxy Group, 2-fluoro-1-methylethoxy group, 2-fluoro-1-
  • Examples of the “C 7 -C 12 aralkyl group” in the substituent group ⁇ include, for example, benzyl group, 1-phenylethyl group, 2-phenylethyl group, 1-phenylpropyl group, 2-phenylpropyl group, 3-phenylpropyl group.
  • benzyl group 1-phenylethyl group, 2-phenylethyl group or 1- A methyl-2-phenylethyl group, more preferably a benzyl group, a 1-phenylethyl group or a 2-phenylethyl group. Particularly preferred is benzyl or 2-phenylethyl.
  • Examples of the “C 7 -C 12 aralkyloxy group” in the substituent group ⁇ include, for example, benzyloxy group, 1-phenylethyloxy group, 2-phenylethyloxy group, 1-phenylpropyloxy group, 2-phenylpropyloxy group Group, 3-phenylpropyloxy group, phenylbutyloxy group, phenylpentyloxy group, phenylhexyloxy group, naphthalen-1-ylmethyloxy group, naphthalen-2-ylmethyloxy group, 1- (naphthalen-1-yl) ) Ethyloxy group, 2- (naphthalen-1-yl) ethyloxy group, 1- (naphthalen-2-yl) ethyloxy group, 2- (naphthalen-2-yl) ethyloxy group, etc., preferably benzyloxy Group, 1-phenylethyloxy group, 2-phenylethyloxy group
  • examples of the “arylene group” represented by Q 1 include a phenylene group or a naphthylene group, and a phenylene group is preferable.
  • aryl group represented by each substituent and the “aryl group” portion in each substituent all mean an “aryl group” having the same significance.
  • Examples of such an “aryl group” include phenyl Group, a naphthyl group, etc. are mentioned, Preferably it is a phenyl group.
  • examples of the “5- to 6-membered heteroarylene group” represented by Q 1 include a furylene group, a thienylene group, a thiazolylene group, a pyridylene group, a pyridazinylene group, and a pyrimidinylene group.
  • a thienylene group, a pyridazinylene group or a pyrimidinylene group particularly preferably a thienylene group.
  • heteroaryl group represented by each substituent and the “heteroaryl group” part in each substituent all mean a “heteroaryl group” having the same significance, and as such a “heteroaryl group”,
  • Examples of the “bicyclic heteroaromatic ring group” represented by Y include, for example, benzofuryl group, benzothienyl group, benzoxazolyl group, benzothiazolyl group, isoindolyl group, indolyl group, indazolyl group, benzoimidazolyl group, isoquinolyl group or quinolyl group.
  • it is a benzofuryl group, a benzothienyl group, a benzoxazolyl group or a benzothiazolyl group, and particularly preferably a benzofuryl group or a benzothienyl group.
  • the “5- to 6-membered ring heterocyclic group” represented by each substituent is 1 to 4 heteroatoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom (in the case of plural, each independently )
  • a ring constituent element which means a fully unsaturated, partially unsaturated or fully saturated 5- to 6-membered cyclic group
  • examples of the fully unsaturated 5- to 6-membered heterocyclic group include pyrrolyl Group, furyl group, thienyl group, pyrazolyl group, imidazolyl group, oxazolyl group, thiazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group or pyrazinyl group, etc., and partially unsaturated 5- to 6-membered heterocyclic group
  • Examples of the fully saturated 5- to 6-membered heterocyclic group include pyrrolidinyl group and tetrahydrofuryl group. 1,3-dioxolanyl group, piperidinyl group, tetrahydropyranyl group, piperazinyl group, morpholinyl group, thiomorpholinyl group, 1,3-dioxanyl group, 1,4-dioxanyl group and the like.
  • the “5- to 6-membered heterocyclic group” represented by each substituent is preferably a thienyl group, pyrazolyl group, oxazolyl group, thiazolyl group, 1,2,4-triazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group.
  • 4,5-dihydrothiazolyl group pyrrolidinyl group or piperidinyl group, more preferably thienyl group, pyrazolyl group, oxazolyl group, thiazolyl group, 1,2,4-triazolyl group, pyridyl group, pyridazinyl group, A pyrimidinyl group or a 4,5-dihydrothiazolyl group, particularly preferably a pyrazolyl group, a thiazolyl group, a 1,2,4-triazolyl group, a pyridyl group, a pyridazinyl group, a pyrimidinyl group or a 4,5-dihydrothiazolyl group.
  • heterocyclic group represented by each substituent means a “heterocyclic group” having the same significance, and such a “heterocyclic group” is a group consisting of an oxygen atom, a nitrogen atom and a sulfur atom.
  • As the partially unsaturated heterocyclic group for example, 4,5-dihydro-1H-imidazolyl group, 4,5-dihydrooxazolyl group, 4,5-dihydrothiazolyl group, 1,4,5, Examples include a 6-tetrahydropyrimidinyl group, a 5,6-dihydro-4H-1,3-oxazinyl group, or a 5,6-dihydro-4H-1,3-thiazinyl group.
  • Examples of the fully saturated heterocyclic group include , Azetidinyl group, pyrrolidinyl group, tetrahydro Group, 1,3-dioxolanyl group, a piperidinyl group, tetrahydropyranyl group, piperazinyl group, morpholinyl group, thiomorpholinyl group, and 1,3-dioxanyl group or a 1,4-dioxanyl group.
  • the “heterocyclic group” represented by each substituent is preferably a 4,5-dihydro-1H-imidazolyl group, an azetidinyl group, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a morpholinyl group, or a thiomorpholinyl group, and more preferably Azetidinyl group, pyrrolidinyl group, piperidinyl group, piperazinyl group or morpholinyl group, particularly preferably azetidinyl group, pyrrolidinyl group or piperidinyl group.
  • halogeno group represented by each substituent and the “halogeno” part in each substituent each mean a “halogeno group” having the same meaning, and such “halogeno group” includes, for example, a fluoro group , A chloro group, a bromo group or an iodo group, preferably a fluoro group, a chloro group or a bromo group.
  • N represents an integer of 1 to 4, particularly preferably 1 to 2.
  • A a halogeno group, a C 1 -C 6 alkyl group, a halogeno C 1 -C 6 alkyl group, a C 1 -C 6 alkoxy group, a halogeno C 1 -C 6 alkoxy group and a C 1 -C 6 alkylthio represented by Y
  • Aryl group excluding halogeno group, C 1 -C 6 alkyl group, halogeno C 1 -C 6 alkyl group, C 1 -C 6 alkoxy group and halogeno C 1 -C 6 alkoxy group as a substituent
  • Substituents in groups excluding halogeno groups, C 1 -C 6 alkyl groups, halogeno C 1 -C 6 alkyl groups, C
  • R 1 is preferably a hydrogen atom or a C 1 -C 4 alkyl group, more preferably a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, or a tert-butyl group, and particularly preferably , Hydrogen atom, methyl group, ethyl group or isopropyl group.
  • R 2 is preferably a hydrogen atom or a C 1 -C 4 alkyl group, more preferably a hydrogen atom or a methyl group, and particularly preferably a hydrogen atom.
  • R 3 is preferably a hydrogen atom or a C 1 -C 4 alkyl group, more preferably a hydrogen atom or a methyl group, and particularly preferably a hydrogen atom.
  • Y is preferably a halogeno group, a C 1 -C 4 alkyl group, a halogeno C 1 -C 4 alkyl group, a C 1 -C 4 alkoxy group, a halogeno C 1 -C 4 alkoxy group and a C 1 -C 4 alkylthio.
  • Z is preferably a halogeno group, a C 7 -C 12 aralkyl group, a C 1 -C 4 alkoxy group, a C 7 -C 12 aralkyloxy group, a C 3 -C 6 cycloalkyl group, or a C 5 -C 6 cyclo group.
  • the compound represented by the general formula (I) of the present invention is easily converted into a pharmacologically acceptable acid addition salt by treating with an acid.
  • salts include inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or phosphate; or acetate, trifluoroacetate, benzoate Oxalate, malonate, succinate, maleate, fumarate, tartrate, citrate, methanesulfonate, ethanesulfonate, trifluoromethanesulfonate, benzenesulfonate, p -Organic acid salts such as toluene sulfonate, glutamate or aspartate.
  • R 1 is a hydrogen atom
  • the compound represented by the general formula (I) of the present invention is easily converted into a pharmacologically acceptable basic salt by treatment with a base.
  • salts include metal salts such as sodium salts, potassium salts, calcium salts, and magnesium salts; inorganic salts such as ammonium salts; and organic amine salts such as triethylamine salts and guanidine salts.
  • the compound represented by the general formula (I) of the present invention or a pharmacologically acceptable salt thereof can exist as a hydrate or a solvate, and these are also included in the present invention.
  • a compound in which R 1 is a hydrogen atom or a C 1 -C 4 alkyl group (2) Compound wherein R 1 is a hydrogen atom, methyl group, ethyl group, propyl group, isopropyl group or tert-butyl group (3) Compound wherein R 1 is a hydrogen atom, methyl group, ethyl group or isopropyl group, (4) the compound wherein R 2 and R 3 are each independently a hydrogen atom or a C 1 -C 4 alkyl group, (5) A compound in which R 2 and R 3 are each independently a hydrogen atom or a methyl group, (6) A compound in which R 2 and R 3 are both hydrogen atoms, (7) Y is a halogeno group, a C 1 -C 4 alkyl group, a halogeno C 1 -C 4 alkyl group, a C 1 -C 4 alkoxy
  • Y is a benzofuran-2-yl group, a benzo [b] thiophen-2-yl group, a 6-chlorobenzo [b] thiophen-2-yl group, or a 6-methoxybenzo [b] thiophen-2-yl group Biphenyl-4-yl group, 4′-fluorobiphenyl-4-yl group, 3′-propylbiphenyl-4-yl group, 4- (pyrazol-1-yl) phenyl group, 4- (thiazol-2-yl) ) Phenyl group, 4- (thiazol-4-yl) phenyl group, 6-phenylpyridazin-3-yl group, 4- (1-methylcyclopropyl) phenyl group, 4- (1-ethylcyclopropyl) phenyl group, 4- (1-isopropylcyclopropyl) phenyl group, 4- (1-butylcyclopropyl) phen
  • R 1 is a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, or a tert-butyl group
  • R 2 and R 3 are each independently a hydrogen atom or a methyl group
  • Y is a group consisting of a halogeno group, a C 1 -C 4 alkyl group, a halogeno C 1 -C 4 alkyl group, a C 1 -C 4 alkoxy group, a halogeno C 1 -C 4 alkoxy group and a C 1 -C 4 alkylthio group
  • Q 1 is a phenylene group, a thienylene group, a pyridazinylene group, which may be substituted with
  • Trifluoromethyl group Trifluoromethyl group, difluoromethyl group, trichloromethyl group, dichloromethyl group, 2,2,2-trifluoroethyl group, 2,2,2-trichloroethyl group, methoxy group, ethoxy group, propoxy group, isopropoxy
  • Z is methyl, ethyl, propyl, isopropyl, trifluoromethyl, 1-phenylethyl, 2-phenylethyl, 2-cyclopropylethyl, 3-dimethylaminopropyl, benzyl, cyclo Propyl group, azetidin-1-yl group, pyrrolidin-1-yl group, piperidin-1-yl group, 4-cyanophenyl group, 4-benzyloxyphenyl group, 4-cyclopropylphenyl group, 4-methoxycarbonylphenyl group 4-methylthiophenyl group, 4-dimethylaminophenyl group, 4-anilinophenyl group, 4-acetylaminophenyl group, 4-methoxycarbonylaminophenyl group, biphenyl-4-yl group, biphenyl-3-yl group, 4-phenoxyphenyl group, 4- (pyrrolidin-1-yl) phenyl group, benzo
  • sulfonamide compound preferably (6- ⁇ (quinolin-8-ylsulfonyl) [4- (thiazol-2-yl) benzyl] aminomethyl ⁇ pyridin-2-ylamino) acetic acid, (6- ⁇ (biphenyl-4-ylsulfonyl) [4- (thiazol-2-yl) benzyl] aminomethyl ⁇ pyridin-2-ylamino) acetic acid, ⁇ 6-[(4-tert-butylbenzyl) (methylsulfonyl) aminomethyl] pyridin-2-ylamino ⁇ acetic acid, ⁇ 6-[(azetidin-1-ylsulfonyl) (4-tert-butylbenzyl) aminomethyl] pyridin-2-ylamino ⁇ acetic acid, (6- ⁇ (4-phenoxybenzenesulfonyl) [4- (thiazol-2-yl) benzyl] amino
  • a pharmaceutical composition comprising as an active ingredient the compound represented by the above general formula (I), the sulfonamide compound according to any one of (1) to (19) or a pharmacologically acceptable salt thereof, And (21) The pharmaceutical composition according to (20) for prevention or treatment of respiratory diseases is also provided.
  • R 2 , R 3 , Y and Z are as defined above, and X represents a hydroxy group, a chloro group, a bromo group, an iodo group, a methanesulfonyloxy group, a benzenesulfonyloxy group, p-toluene. indicates sulfonyloxy group or a trifluoromethanesulfonyloxy group, Boc represents a tert- butoxycarbonyl group, Bu t represents a tert- butyl group. ]
  • Synthetic pathways 1 to 3 Compound A of the present invention by reacting compound A and compound B, or compound C and compound D, or compound E and compound F in an organic solvent in the presence of a condensing agent or a base, respectively.
  • Compound (I ′) which is a precursor of Compounds of the invention wherein R 1 is a hydrogen atom (Ia) may be a precursor compound of the Boc group and Bu t group (I ') obtained by deprotection by acid treatment.
  • the substituent on the substituent Y and / or the substituent Z may have a desired substituent introduced from the beginning, and after the basic skeleton is produced by the above method, oxidation, reduction, alkylation, Esterification, amidation, dehydration reaction, deprotection reaction, acetylation, hydrolysis, coupling reaction, cyclization reaction and / or a general synthetic method combining these reactions can be used as desired for the basic skeleton. Substituents may be introduced.
  • the method for producing the synthetic intermediate of the compound of the present invention will be described in detail in the Examples below.
  • the target compound produced in each reaction can be obtained from the reaction mixture according to a conventional method.
  • the reaction mixture is appropriately neutralized, and if insoluble matter is present, it is removed by filtration, and then an organic solvent such as ethyl acetate that is immiscible with water is added.
  • It isolate separates and it obtains by distilling a solvent off after drying with desiccants, such as anhydrous magnesium sulfate or anhydrous sodium sulfate.
  • the obtained target compound can be obtained by a conventional method such as recrystallization; reprecipitation; or a method commonly used for separation and purification of organic compounds (for example, adsorption column chromatography using a carrier such as silica gel or alumina).
  • the compound represented by the general formula (I) of the present invention can be converted into a pharmacologically acceptable salt according to a conventional method, if necessary, but can also be separated directly from the reaction mixture as a salt.
  • the compound represented by the general formula (I) of the present invention or a pharmacologically acceptable salt thereof can be administered as it is (as it is in the bulk) or an appropriate pharmacology.
  • Oral or parenteral intravenous, intramuscular, intraperitoneal, transdermal, transrespiratory, intradermal, or subcutaneous
  • suppositories ointments, lotions, inhalants or injections Etc.
  • additives such as excipients, lubricants, binders, disintegrants, emulsifiers, stabilizers, flavoring agents or diluting seats.
  • Excipients include, for example, organic excipients or inorganic excipients.
  • organic excipient include sugar derivatives such as lactose, sucrose, glucose, mannitol or sorbitol; starch derivatives such as corn starch, potato starch, ⁇ -starch or dextrin; cellulose derivatives such as crystalline cellulose; gum arabic; Dextran; or pullulan and the like.
  • inorganic excipients include light anhydrous silicic acid; or sulfates such as calcium sulfate.
  • Lubricants include, for example, stearic acid; stearic acid metal salts such as calcium stearate or magnesium stearate; talc; colloidal silica; waxes such as beeswax or gallow; boric acid; adipic acid; sulfate such as sodium sulfate; glycol Fumaric acid; sodium benzoate; D, L-leucine; sodium lauryl sulfate; silicic acids such as anhydrous silicic acid or silicic acid hydrate; or starch derivatives in the above-mentioned excipients.
  • binder examples include hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, macrogol, and compounds represented by the above excipients.
  • Disintegrants include, for example, cellulose derivatives such as low substituted hydroxypropylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium or internally crosslinked carboxymethylcellulose calcium; crosslinked polyvinylpyrrolidone; or chemically modified starch such as carboxymethyl starch or sodium carboxymethyl starch Or a cellulose derivative is mentioned.
  • the emulsifier is, for example, colloidal clay such as bentonite or bee gum; an anionic surfactant such as sodium lauryl sulfate; a cationic surfactant such as benzalkonium chloride; or polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester Or nonionic surfactants, such as sucrose fatty acid ester, etc. are mentioned.
  • Stabilizers include, for example, parahydroxybenzoates such as methylparaben or propylparaben; alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol; benzalkonium chloride; phenols such as phenol or cresol; thimerosal; acetic anhydride Or sorbic acid.
  • parahydroxybenzoates such as methylparaben or propylparaben
  • alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol
  • benzalkonium chloride phenols such as phenol or cresol
  • thimerosal acetic anhydride Or sorbic acid.
  • sweeteners such as saccharin sodium or aspartame
  • acidulants such as citric acid, malic acid or tartaric acid
  • flavors such as menthol, lemon extract or orange extract.
  • Diluents are compounds that are commonly used as diluents, such as lactose, mannitol, glucose, sucrose, calcium sulfate, hydroxypropylcellulose, microcrystalline cellulose, water, ethanol, polyethylene glycol, propylene glycol, glycerol, starch , Polyvinylpyrrolidone or a mixture thereof.
  • the dose of the compound represented by the general formula (I) of the present invention or a pharmacologically acceptable salt thereof can vary depending on conditions such as the patient's symptoms, age, body weight, etc.
  • the lower limit is 0.001 mg / Kg (preferably 0.01 mg / Kg) and the upper limit is 20 mg / Kg (preferably 10 mg / Kg) per dose.
  • the lower limit is 0.0001 mg per dose.
  • / Kg preferably 0.0005 mg / Kg
  • an upper limit of 10 mg / Kg preferably 5 mg / Kg
  • Rf values in the examples, thin layer chromatography is a value measured using a (Merck, TLC plate silica gel 60F 254 (trade name)), is described in parentheses represent the developing solvent (volume ratio) .
  • reaction solution was concentrated under reduced pressure, water and saturated aqueous sodium hydrogen carbonate solution were added to the residue, and the mixture was extracted with ethyl acetate.
  • the organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
  • test compound dissolved in dimethyl sulfoxide and [ 3 H] prostaglandin E 2 (NET-428, manufactured by PerkinElmer) (final concentration: 10 nM) were added, and incubated at 30 ° C. for 60 minutes.
  • NET-428 [ 3 H] prostaglandin E 2
  • the membrane fraction was collected on glass fiber filter paper (GF / B, Whatman) and buffered (10 mM MES-KOH (pH 6.0), 10 mM MgCl 2 ). ), And the radioactivity was measured with a liquid scintillation analyzer (2000 CA, manufactured by Packard).
  • EXSAS version 7.1.6, manufactured by Arm Systex
  • IC 50 value concentration of the test compound required to replace 50% of [ 3 H] prostaglandin E 2 bound to the receptor.
  • the dissociation constant (Kd value) was calculated by Scatchard analysis. The test results are shown in Table 1.
  • the compound of the present invention showed an excellent EP2 receptor binding action.
  • EP2 agonist activity was measured according to the method of Wilson et al. (European Journal of Pharmacology, 501, 49 (2004)).
  • HEK293 cells ES-562-C, manufactured by Euroscreen
  • HEK293 cells expressing human EP2 receptor were cultured in MEM medium containing 10% FBS, and 2 ⁇ 10 4 cells were seeded in 96-well plates. The next day, the medium was replaced with a serum-free MEM medium containing 3-isobutyl-1-methylxanthine (final concentration 500 ⁇ M) and incubated for 30 minutes, and then the test compound dissolved in dimethyl sulfoxide was added and left in a carbon dioxide incubator.
  • the amount of intracellular cAMP was measured with a cAMP Biotrak EIA System kit (GE Healthcare Bioscience).
  • concentration (EC 50 value) of the test compound required to raise cAMP to 50% of the maximum increase amount was calculated using EXSAS by nonlinear regression between the test compound concentration and the cAMP amount.
  • the compound of the present invention showed excellent EP2 agonist activity.
  • Formulation Example 1 (Hard Capsule) 50 mg of the powdered compound of Example 7, 128.7 mg of lactose, 70 mg of cellulose and 1.3 mg of magnesium stearate were mixed, passed through a 60 mesh sieve, and 250 mg of this powder was put into a No. 3 gelatin capsule. Into capsules.
  • Formulation Example 2 (Tablet) 50 mg of the compound of Example 7, 124 mg of lactose, 25 mg of cellulose and 1 mg of magnesium stearate are mixed, and tableted by a tableting machine to make one tablet of 200 mg. This tablet can be sugar-coated if necessary.
  • the sulfonamide compound represented by the general formula (I) of the present invention or a pharmacologically acceptable salt thereof exhibits an excellent bronchodilator action based on a strong EP2 agonist action, and further, tissue transferability, bioavailability (bioavailability). BA), rapid onset of drug efficacy, sustained drug efficacy, solubility, physical stability, drug interaction, toxicity, etc., and also has excellent properties as a pharmaceutical compound.
  • a medicament for the treatment and / or prevention of respiratory diseases eg, asthma, COPD, bronchitis, emphysema, pulmonary fibrosis, acute respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary hypertension, etc.
  • respiratory diseases eg, asthma, COPD, bronchitis, emphysema, pulmonary fibrosis, acute respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary hypertension, etc.
  • ARDS acute respiratory distress syndrome
  • cystic fibrosis pulmonary hypertension
  • the treatment and / or prognosis of diseases for example, bone diseases, gastric ulcers, hypertension, glaucoma, etc.
  • EP2 agonist action for which EP2 agonist action may be useful are useful.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet de nouveaux composés sulfonamide représentés par la formule générale (I), qui présentent un excellent effet bronchodilatateur qui dépend d'une activité puissante d'agoniste d'EP2; ou leurs sels.
PCT/JP2010/065658 2009-09-11 2010-09-10 Composés sulfonamide WO2011030872A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009210788 2009-09-11
JP2009-210788 2009-09-11

Publications (1)

Publication Number Publication Date
WO2011030872A1 true WO2011030872A1 (fr) 2011-03-17

Family

ID=43732539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/065658 WO2011030872A1 (fr) 2009-09-11 2010-09-10 Composés sulfonamide

Country Status (1)

Country Link
WO (1) WO2011030872A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012201674A (ja) * 2011-03-28 2012-10-22 Kagoshima Univ 抗ｈｉｖ薬
WO2014157672A1 (fr) 2013-03-28 2014-10-02 宇部興産株式会社 Composé biaryle substitué
WO2015030250A1 (fr) 2013-09-02 2015-03-05 宇部興産株式会社 Composition pharmaceutique pour le traitement et/ou la prévention d'une maladie pulmonaire

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027053A1 (fr) * 1996-12-18 1998-06-25 Ono Pharmaceutical Co., Ltd. Derives de sulfamide et de carboxamide, et medicaments contenant ces derives en tant que principe actif
JP2006519250A (ja) * 2003-03-04 2006-08-24 ファイザー・プロダクツ・インク 医療処置におけるｅｐ２選択的受容体アゴニストの使用
JP2007515467A (ja) * 2003-12-22 2007-06-14 アステランド ユーケイ リミテッド Ｅｐ２受容体アゴニスト
JP2007186424A (ja) * 2004-11-26 2007-07-26 Ono Pharmaceut Co Ltd 気管支拡張剤
WO2008015517A2 (fr) * 2006-07-28 2008-02-07 Pfizer Products Inc. Agonistes de ep2
JP2009502982A (ja) * 2005-08-03 2009-01-29 メルク フロスト カナダ リミテツド Ｅｐ４受容体アゴニスト、この組成物および方法
WO2009113600A1 (fr) * 2008-03-12 2009-09-17 宇部興産株式会社 Composé d'acide pyridylaminoacétique

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027053A1 (fr) * 1996-12-18 1998-06-25 Ono Pharmaceutical Co., Ltd. Derives de sulfamide et de carboxamide, et medicaments contenant ces derives en tant que principe actif
JP2006519250A (ja) * 2003-03-04 2006-08-24 ファイザー・プロダクツ・インク 医療処置におけるｅｐ２選択的受容体アゴニストの使用
JP2007515467A (ja) * 2003-12-22 2007-06-14 アステランド ユーケイ リミテッド Ｅｐ２受容体アゴニスト
JP2007186424A (ja) * 2004-11-26 2007-07-26 Ono Pharmaceut Co Ltd 気管支拡張剤
JP2009502982A (ja) * 2005-08-03 2009-01-29 メルク フロスト カナダ リミテツド Ｅｐ４受容体アゴニスト、この組成物および方法
WO2008015517A2 (fr) * 2006-07-28 2008-02-07 Pfizer Products Inc. Agonistes de ep2
WO2009113600A1 (fr) * 2008-03-12 2009-09-17 宇部興産株式会社 Composé d'acide pyridylaminoacétique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAMERON, K. 0.: "Discovery of CP-533536: An EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 7, 2009, pages 2075 - 2078 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012201674A (ja) * 2011-03-28 2012-10-22 Kagoshima Univ 抗ｈｉｖ薬
WO2014157672A1 (fr) 2013-03-28 2014-10-02 宇部興産株式会社 Composé biaryle substitué
EP2980075A4 (fr) * 2013-03-28 2016-08-10 Ube Industries Composé biaryle substitué
US9676720B2 (en) 2013-03-28 2017-06-13 Ube Industries, Ltd. Substituted biaryl compound
WO2015030250A1 (fr) 2013-09-02 2015-03-05 宇部興産株式会社 Composition pharmaceutique pour le traitement et/ou la prévention d'une maladie pulmonaire

Similar Documents

Publication Publication Date Title
RU2678830C2 (ru) Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз
KR101589332B1 (ko) ２ｈ-크로멘 화합물 및 그의 유도체
JP5095736B2 (ja) ６−１ｈ−イミダゾ−キナゾリンおよびキノリン誘導体、新規有効鎮痛剤および抗炎症剤
JP2009511529A (ja) キナーゼ阻害剤
PT1492786E (pt) Piridinoilpiperidinas como agonistas do 5-ht1f
AU2008286027A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
JP2001514227A (ja) ピラジノン系トロンビン阻害薬
JP2014515029A (ja) キナーゼ阻害剤
JP2007510750A (ja) トロンビンレセプターアンタゴニストの使用方法
CN110997653A (zh) 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂
CA2767992C (fr) Benzene-sulfonate de 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide, cristaux de celui-ci, ses polymorphes et ses procedes de fabrication
MX2007005340A (es) Novedosas piridinurea nicotinamidas como inhibidores de quinasas de receptores del factor de crecimiento del endotelio vascular (vegf).
EP3418277A1 (fr) Composé à cycle hétérocyclique nitrique à six éléments amino substitué, sa préparation et son utilisation
WO2011030872A1 (fr) Composés sulfonamide
US20120226036A1 (en) Substituted carbonyl compound
AU2006319984A1 (en) Acid addition salt of optically active dihydropyridine derivative
KR20160116009A (ko) 암 및 증식성 장애들의 치료를 위한 유사분열억제성 아마이드들
WO2011030865A1 (fr) Composés benzyliques substitués
EP2476668B1 (fr) Composés aniline
WO2011030873A1 (fr) Composés benzyliques
US20120259123A1 (en) Aminopyridine compound
WO2011030871A1 (fr) Composés hétéroaryle n-substitués
JP7144863B2 (ja) イソキノリン化合物、その調製の方法、およびベータガラクトシダーゼの活性の変質に伴う状態におけるその治療的使用
AU2017293946A1 (en) Indoline derivatives and method for using and producing the same
MX2014001052A (es) Compuesto novedoso que tiene actividad inhibidora de angiogénesis, metodo para preparar del mismo, y composicion farmaceutica que comprende el mismo.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10815466

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10815466

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP